Kailera Therapeutics
About Kailera Therapeutics
Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a broad and advanced therapeutic pipeline that is poised to deliver differentiated treatment options for obesity and related conditions.
Recent News
Keep an Eye on These 15 Biotech Companies in 2026
Early-Stage Biotechs Suffer in 2025 As VC Shuns Risk: PitchBook
Labiotech’s 15 Biopharma Companies to Watch in 2026
Nine Biotech Companies that Could Revolutionize Obesity Treatments
Hengrui, Kailera Tout Positive Results for Dual-Acting Obesity Pill
2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now?
Recent Deals
Kailera Raises $1bn in Growth-Stage Funding Round
Kailera Therapeutics Files IPO to Fund Dual GLP-1/GIP Obesity Drug Development
Kailera Therapeutics Secures $600M Series B Funding Led by Bain Capital Private Equity
Kailera Therapeutics Eyes Record $533M IPO to Target Obesity Market
